Moderna, Inc. Common Stock (MRNA) Financials
Key financial figures for Moderna, Inc. Common Stock (Q2 2026).
Moderna's Q2 2026 revenue was $145 million, roughly flat year-over-year, while the company narrowed full-year 2026 R&D expense guidance to approximately $2.9 billion and raised its year-end cash outlook to $4.7-$5.2 billion. Total revenue was $145 million for the quarter ended June 30, 2026, essentially flat versus $142 million in Q2 2025. Net loss was $782 million, or $(1.97) per share, narrower than the $(2.13) per share loss a year ago, as R&D expense declined to $651 million from $700 million in Q2 2025. Operating loss narrowed to $(815) million from $(907) million in Q2 2025, tracking the lower R&D spend. Cash, cash equivalents and investments totaled $6.9 billion as of June 30, 2026, up sequentially from $5.77 billion at the end of Q1 2026, though down from $7.5 billion a year earlier. On the outlook: For full-year 2026, Moderna guided to approximately $2.9 billion in R&D expense and $4.7 billion to $5.2 billion in year-end cash, cash equivalents and investments. Figures are for Q2 2026, as Moderna Inc. reported them.
- Revenue
- $145M
- Net Income
- -$782M
- EPS
- $-1.97
- Total Assets
- $11.0B
- Operating Cash Flow
- -$526M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $145M | -$782M | -$1.96 | -562.07% | -$563M |
| Q1 FY2026 | $389M | -$1.3B | -$3.40 | -356.81% | -$692M |
| Q4 FY2025 | $678M | -$826M | -$2.11 | -126.4% | $912M |
| Q3 FY2025 | $1.0B | -$200M | -$0.51 | -25.59% | -$880M |
| Q2 FY2025 | $142M | -$825M | -$2.13 | -638.73% | -$922M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.9B | -$2.8B | -$7.26 | -158.13% | -$2.1B |
| FY2024 | $3.2B | -$3.6B | -$9.27 | -123.32% | -$4.1B |
| FY2023 | $6.8B | -$4.7B | -$12.34 | -61.9% | -$3.8B |
Frequently asked questions
What was Moderna Inc.'s revenue last quarter?
Moderna Inc. reported revenue of $145.0 million for Q2 FY2026, up 2.1% from the same period a year earlier.
Is Moderna Inc. profitable?
Not in its most recent reported period. Moderna Inc. reported a net loss of $782.0 million for Q2 FY2026, a net margin of -539.31% on revenue.
How has Moderna Inc.'s margin trended?
Operating margin was -562.07% in Q2 FY2026, compared with -638.73% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Moderna Inc. generate?
Moderna Inc. generated free cash flow of -$563.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Moderna, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.